Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) issued its earnings results on Thursday. Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 39.56%. Here are the key takeaways from Lexicon Pharmaceuticals’ conference call:Get Lexicon Pharmaceuticals alerts:SONATA-HCM enrollment was completed significantly ahead of plan , with the Phase 3 trial including both obstructive and non-obstructive HCM patients. Lexicon Pharmaceuticals Stock PerformanceShares of Lexicon Pharmaceuticals stock traded up $0.11 during trading hours on Friday, reaching $2.47. Read MoreReceive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.